Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL

Blood

Volumn 128, Issue 6, 2016, Pages 774-782

  Rousselot, Philippe ^a,b   Coudé, Marie Magdelaine ^c,d   Gokbuget, Nicola ^e   Passerini, Carlo Gambacorti ^f   Hayette, Sandrine ^g   Cayuela, Jean Michel ^c,d   Huguet, Françoise ^h   Leguay, Thibaut ⁱ   Chevallier, Patrice ^j   Salanoubat, Celia ^k   Bonmati, Caroline ^l   Alexis, Magda ^m   Hunault, Mathilde ^n,o   Glaisner, Sylvie ^p   Agape, Philippe ^q   Berthou, Christian ^r   Jourdan, Eric ^s   Fernandes, José ^t   Sutton, Laurent ^u   Banos, Anne ^v   Reman, Oumedaly ^w   Lioure, Bruno ^x   Thomas, Xavier ^g   Ifrah, Norbert ^n,o   Lafage Pochitaloff, Marina ^y   Bornand, Anne ^a   Morisset, Laure ^a   Robin, Valérie ^z   Pfeifer, Heike ^e   Delannoy, Andre ^aa   Ribera, Josep ^ab   Bassan, Renato ^ac   Delord, Marc ^ad   Hoelzer, Dieter ^e   Dombret, Herve ^c   Ottmann, Oliver G ^ae   more..

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e GOETHE UNIVERSITY   (Germany)

^f UNIVERSITY OF MILANO BICOCCA   (Italy)

^g CNRS   (France)

^h Institut Universitaire de Cancérologie   (France)

ⁱ HAUT LÉVÊQUE HOSPITAL   (France)

^j HÔTEL DIEU   (France)

^k CENTRE HOSPITALIER SUD FRANCILIEN   (France)

^l CHU NANCY BRABOIS   (France)

^m CENTRE HOSPITALIER RÉGIONAL D ORLÉANS   (France)

ⁿ ANGERS UNIVERSITY HOSPITAL   (France)

^o Team 12   (France)

^p INSTITUT CURIE   (France)

^q Centre Hospitalier Universitaire Félix Guyon   (Reunion)

^r BREST UNIVERSITY HOSPITAL   (France)

^s NÎMES UNIVERSITY HOSPITAL   (France)

^t Hematology Immunology and Cytogenetics Department   (France)

^u CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^v CENTRE HOSPITALIER DE LA CÔTE BASQUE   (France)

^w CAEN UNIVERSITY HOSPITAL   (France)

^x HÔPITAL DE HAUTEPIERRE   (France)

^y AIX MARSEILLE UNIVERSITY   (France)

^z CHR Mons Hainaut   (Belgium)

^aa Haine Saint Paul   (Belgium)

^ab HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^ac Azienda ULSS 12 Veneziana Direttore UOC Ematologia   (Italy)

^ad UNIVERSITÉ PARIS DIDEROT   (France)

^ae CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; BCR ABL PROTEIN; CYTARABINE; DASATINIB; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE; ANTINEOPLASTIC AGENT; BCR-ABL1 FUSION PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ATRIAL FIBRILLATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; COMORBIDITY; CONSOLIDATION CHEMOTHERAPY; DIGESTIVE SYSTEM HEMORRHAGE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HEART FAILURE; HUMAN; HYPERTRANSAMINASEMIA; INTERSTITIAL PNEUMONIA; KIDNEY FAILURE; LEUKOCYTE COUNT; LONG TERM SURVIVAL; LUNG ASPERGILLOSIS; LUNG EMBOLISM; LYMPHOCYTOSIS; MAINTENANCE CHEMOTHERAPY; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; MYELOABLATIVE CONDITIONING; NEUTROPENIA; OVERALL SURVIVAL; PERICARDIAL EFFUSION; PHILADELPHIA 1 CHROMOSOME; PHILADELPHIA CHROMOSOME POSITIVE CELL; PLEURA EFFUSION; PNEUMOCYSTIS PNEUMONIA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REDUCED INTENSITY CONDITIONING; SUBDURAL HEMATOMA; TREATMENT DURATION; TUMOR LYSIS SYNDROME; DRUG EFFECTS; GENETICS; MIDDLE AGED; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DASATINIB; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; MALE; MIDDLE AGED; MUTATION; PHILADELPHIA CHROMOSOME; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS;

EID: 84981541240     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-02-700153     Document Type: Article

References (28)

1. Burmeister T, Schwartz S, Bartram CR, Gökbuget N, Hoelzer D, Thiel E; GMALL study group. Patients' age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group. Blood. 2008; 112 (3): 918-919.
2. Annino L, Goekbuget N, Delannoy A. Acute lymphoblastic leukemia in the elderly. Hematol J. 2002; 3 (5): 219-223.
3. Mullighan CG, Williams RT, Downing JR, Sherr CJ. Failure of CDKN2A/B (INK4A/B-ARF)- mediated tumor suppression and resistance to targeted therapy in acute lymphoblastic leukemia induced by BCR-ABL. Genes Dev. 2008; 22 (11): 1411-1415.
4. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002; 100 (6): 1965-1971.
5. Delannoy A, Delabesse E, Lhéritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia. 2006; 20 (9): 1526-1532.
6. Ottmann OG, Wassmann B, Pfeifer H, et al; GMALL Study Group. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph1ALL). Cancer. 2007; 109 (10): 2068-2076.
7. Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007; 109 (9): 3676-3678.
8. Rea D, Legros L, Raffoux E, et al; Intergroupe Français des Leucémies Myéloîdes Chronique; Group for Research in Adult Acute Lymphoblastic Leukemia. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia. 2006; 20 (3): 400-403.
9. Santos FP, Cortes J. Dasatinib for the treatment of Philadelphia chromosome-positive leukemias. Expert Opin Pharmacother. 2012; 13 (16): 2381-2395.
10. Benjamini O, Dumlao TL, Kantarjian H, et al. Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014; 89 (3): 282-287.
11. Schwartz P, Hunault-Berger M, Chevallier PL, et al. French results with the EWALL chemotherapy backbone in older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. A GRAALL report. [abstract]. Haematologica. 2013; 98 (S1): 463. Abstract S1124.
12. Miller MD, Towers A. A Manual of Guidelines for Scoring the Cumulative Illness Rating Scale for Geriatrics. Pittsburgh, PA: University of Pittsburgh; 1991.
13. Brüggemann M, Schrauder A, Raff T, et al; European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL); International Berlin-Frankfurt-Münster Study Group (I-BFMSG). Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia. 2010; 24 (3): 521-535.
14. Aalen O. Nonparametric estimation of partial transition probabilities in multiple decrement models. Ann Stat. 1978; 6 (3): 534-545.
15. Bergeron A, Réa D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007; 176 (8): 814-818.
16. Ribera JM, García O, Oriol A, et al; PETHEMA Group, Spanish Society of Hematology. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA group. Leuk Res. 2016; 41: 12-20.
17. Foà R, Vitale A, Vignetti M, et al; GIMEMA Acute Leukemia Working Party. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011; 118 (25): 6521-6528.
18. Ravandi F, O'Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015; 121 (23): 4158-4164.
19. Porkka K, Koskenvesa P, Lundán T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008; 112 (4): 1005-1012.
20. Ravandi F, Jorgensen JL, Thomas DA, et al. Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013; 122 (7): 1214-1221.
21. Chalandon Y, Thomas X, Hayette S, et al; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL). Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015; 125 (24): 3711-3719.
22. Shah NP, Guilhot F, Cortes JE, et al. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: followup of a phase 3 study. Blood. 2014; 123 (15): 2317-2324.
23. Soverini S, Vitale A, Poerio A, et al. Philadelphiapositive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis. Haematologica. 2011; 96 (4): 552-557.
24. Pfeifer H, Lange T, Wystub S, et al. Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia. Leukemia. 2012; 26 (7): 1475-1481.
25. Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015; 16 (15): 1547-1555.
26. DeBoer R, Koval G, Mulkey F, et al. Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph1) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665 [published online ahead of print 18 February 2016]. Leuk Lymphoma.
27. Jabbour E, O'Brien S, Ravandi F, Kantarjian H. Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 2015; 125 (26): 4010-4016.
28. Le Jeune C, Thomas X. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia. Drug Des Devel Ther. 2016; 10: 757-765.